Arne Høst

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.

Background:u2002 3‐year subcutaneous specific immunotherapy (SIT) in children with seasonal allergic rhinoconjunctivitis reduced the risk of developing asthma during treatment and 2u2003years after discontinuation of SIT (5‐year follow‐up) indicating long‐term preventive effect of SIT.

Five-year follow-up on the PAT study : specific immunotherapy and long-term prevention of asthma in children

Background:u2002 A 3‐year course of specific immunotherapy (SIT) in children with hay fever to grass and/or birch pollen significantly reduced the risk of developing asthma. To investigate the long‐term preventive effect, we performed a follow up – 2u2003years after termination of immunotherapy.

European birth cohort studies on asthma and atopic diseases: I. Comparison of study designs – a GA2LEN initiative

Background:u2002 The reasons for the rise in asthma and allergies remain unclear. To identify risk or protective factors, it is essential to carry out longitudinal epidemiological studies, preferably birth cohort studies. In Europe, several birth cohort studies on asthma and atopic diseases have been initiated over the last two decades.

European birth cohort studies on asthma and atopic diseases: II. Comparison of outcomes and exposures – a GA2LEN initiative

Background:u2002 The Global Allergy and Asthma European Network (GA2LEN) is a consortium of 26 leading European research centres committed to establish a European research area of excellence in the field of allergy and asthma.